Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial

Abstract Background Dual bronchodilation combining a long-acting β2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) is the preferred choice of treatment recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 guidelines for the management of patients with...

Full description

Bibliographic Details
Main Authors: Claus F. Vogelmeier, Mina Gaga, Maryam Aalamian-Mattheis, Timm Greulich, Jose M. Marin, Walter Castellani, Vincent Ninane, Stephen Lane, Xavier Nunez, Francesco Patalano, Andreas Clemens, Konstantinos Kostikas, on behalf of the CRYSTAL study investigators
Format: Article
Language:English
Published: BMC 2017-07-01
Series:Respiratory Research
Subjects:
Chronic obstructive pulmonary disease
Dual bronchodilation
Indacaterol/glycopyrronium
Direct switch
Open-label
Online Access:http://link.springer.com/article/10.1186/s12931-017-0622-x

Internet

http://link.springer.com/article/10.1186/s12931-017-0622-x

Similar Items